Commentary : SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol
© 2019 John Wiley & Sons Ltd..
In the accompanying article, Goldenberg et al. review the promotion of diabetic ketoacidosis by SGLT2 inihibitors. They have carried out a metanalysis showing a 3.5-fold increase in the risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes under treatment with SGLT2 inhibitors. They make a number of suggestions for attempting to mitigate the risk of DKA in these patients, notably including blood ketone monitoring and the use of supplemental carbohydrates with additional insulin when ketones suggest incipient DKA. Their proposal merits evaluation in a clinical trial involving type 1 diabetes, which should also assess the possible cardiorenal benefits demonstrated with treatment with SGLT2 inhibitors in type 2 diabetes.
| Errataetall: |
CommentOn: Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. - PMID 31183975 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 21(2019), 10 vom: 07. Okt., Seite 2189-2191 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rendell, Marc S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NEZ333N27 |
|---|
| Anmerkungen: |
Date Completed 04.03.2020 Date Revised 04.03.2020 published: Print-Electronic CommentOn: Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. - PMID 31183975 Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.13836 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299469123 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299469123 | ||
| 003 | DE-627 | ||
| 005 | 20231225100413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.13836 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299469123 | ||
| 035 | |a (NLM)31334593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rendell, Marc S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Commentary |b SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2020 | ||
| 500 | |a Date Revised 04.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Diabetes Obes Metab. 2019 Oct;21(10):2192-2202. - PMID 31183975 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 John Wiley & Sons Ltd. | ||
| 520 | |a In the accompanying article, Goldenberg et al. review the promotion of diabetic ketoacidosis by SGLT2 inihibitors. They have carried out a metanalysis showing a 3.5-fold increase in the risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes under treatment with SGLT2 inhibitors. They make a number of suggestions for attempting to mitigate the risk of DKA in these patients, notably including blood ketone monitoring and the use of supplemental carbohydrates with additional insulin when ketones suggest incipient DKA. Their proposal merits evaluation in a clinical trial involving type 1 diabetes, which should also assess the possible cardiorenal benefits demonstrated with treatment with SGLT2 inhibitors in type 2 diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Dapagliflozin | |
| 650 | 4 | |a canagliflozin | |
| 650 | 4 | |a diabetes complications | |
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 21(2019), 10 vom: 07. Okt., Seite 2189-2191 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2019 |g number:10 |g day:07 |g month:10 |g pages:2189-2191 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.13836 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2019 |e 10 |b 07 |c 10 |h 2189-2191 | ||